Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pernix Therapeutics, a US based developer of branded and generic pharmaceutical products, has rolled out prescription-based Natroba (spinosad) Topical Suspension, 0.9% for head lice, indicated for the patients four years and above.
Subscribe to our email newsletter
The trial evaluating Natroba demonstrated efficacy against permethrin 1% without nit combing.
In Phase III clinical studies, Natroba was shown to be more effective at eliminating head lice infestations than permethrin 1%.
Pernix president and CEO Cooper Collins said Natroba is an important new, easy to use and effective treatment option for parents of children suffering from a head lice infestation.
"We are pleased that the product is available for the upcoming school year," Collins said.